This is a research study of a new agent used for evaluation of inflammation in the GI tract. This agent is investigational and thus is being studied to determine appropriate dosing and administration in both normal controls (i.e. people without gastrointestinal complaints) and patients with eosinophilic disease (i.e. those with an immune reaction and inflammation in their bodies with a certain cell called an eosinophil). The study will test whether the radiolabeled agent will bind to the inflammation of eosinophilic esophagitis patients because an animal model of eosinophilic esophagitis which shows the striking deposition of eosinophil granule proteins is not available.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Enrollment
8
imaging scan from a person's eyes to their thighs
imaging scan taken during, and after, the administration of the radioactive agent
subjects are administered radioactive heparin as part of study participation.
2 dimensional imaging - whole body planar scans
esophagogastroduodenoscopy with tissue biopsies
University of Utah
Salt Lake City, Utah, United States
Biodistribution of Tc99m-heparin
Biodistribution of Tc99m-heparin to the esophagus and other organs, especially of the gastrointestinal tract as judged by planar scans and by single photon emission computed tomography scans.
Time frame: over approximately 24-26 hours
Calculation of organ doses
Calculation of organ doses from the oral administration of Tc99m-heparin. The organ doses will be measured in miliSieverts using a computer program called OLINDA (Version 2).
Time frame: over approximately 24-26 hours
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.